Management of agitation in the acute psychotic patient - Efficacy without excessive sedation

European Neuropsychopharmacology

Volumn 17, Issue SUPPL. 2, 2007, Pages

  Cañas, Fernando ^a  

^a Hospital Dr Rodríguez Lafora   (Spain)

Author keywords

Acute agitation; Atypical antipsychotics; Intramuscular; Schizophrenia; Sedation

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; HALOPERIDOL; LORAZEPAM; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ACUTE PSYCHOSIS; AGITATION; AKATHISIA; ARTICLE; BRADYCARDIA; CLINICAL TRIAL; DRUG DEPENDENCE; DRUG EFFICACY; DRUG INDICATION; DRUG TOLERABILITY; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HYPOTENSION; INCIDENCE; MUSCLE HYPERTONIA; PARKINSONISM; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZATION; RATING SCALE; RESPIRATION DEPRESSION; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SOMNOLENCE; TREATMENT OUTCOME; TREATMENT RESPONSE; TREMOR;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; HUMANS; INJECTIONS, INTRAMUSCULAR; PSYCHOMOTOR AGITATION; PSYCHOTIC DISORDERS;

EID: 33847321982     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2007.02.004     Document Type: Article

References (33)

1. Allen M.H., Currier G.W., Hughes D.H., Reyes-Harde M., Docherty J.P., and Expert Consensus Panel for Behavioral Emergencies. The expert consensus guideline series: treatment of behavioral emergencies. Postgrad. Med. Special Rep. (2001) (May, 1-88)
2. Allen M.H., Currier G.W., Carpenter D., Ross R.W., and Docherty J.P. Expert consensus guidelines on the treatment of behavioral emergencies. J. Psychiatr. Pract. 11 Suppl. 1 (2005) 1-108
3. American Psychiatric Association (APA). Practice Guideline for the Treatment of Patients with Schizophrenia (2004), American Psychiatric Press, Washington, DC February
4. Andrezina R., Marcus R.N., Oren D.A., Manos G., Stock E., Carson W.H., and McQuade R.D. Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: sub-analysis of a double-blind study. Current Medical Research and Opinion 22 (2006) 2209-2219
5. AstraZeneca Pharmaceuticals LP. Quetiapine (Seroquel) Package Insert (2003), AstraZeneca Pharmaceuticals LP, Willmington, DE, USA
6. Battaglia J. Pharmacological management of acute agitation. Drugs 65 (2005) 1207-1222
7. Begg D.P., Hallam K.T., and Norman T.R. Attenuation of benzodiazepine withdrawal anxiety in the rat by serotonin antagonists. Behav. Brain Res. 161 (2005) 286-290
8. Breier A., Meehan K., Birkett M., David S., Ferchland I., Sutton V., Taylor C.C., Palmer R., Dossenbach M., Kiesler G., Brook S., and Wright P. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch. Gen. Psychiatry 59 (2002) 441-448
9. Bristol-Myers Squibb Co. Aripiprazole (Abilify) Package Insert (2003), Bristol-Myers Squibb Co., Princeton, NJ, USA
10. Brook S., Lucey J.V., and Gunn K.P. Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis. J. Clin. Psychiatry 61 (2000) 933-941
11. Burris K.D., Molski T.F., Xu C., Ryan E., Tottori K., Kikuchi T., Yocca F.D., and Molinoff P.B. Aripiprazole, a novel antipsychotic, is a high affinity partial agonist at human dopamine D2 receptors. J. Pharmacol. Exp. Ther. 302 (2002) 381-389
12. Clark R.E., Xie H., and Brunette M.F. Benzodiazepine prescription practices and substance abuse in persons with severe mental illness. J. Clin. Psychiatry 65 (2004) 151-155
13. Corrigan J.D. Development of a scale for assessment of agitation following traumatic brain injury. J. Clin. Exp. Neuropsychol. 11 (1989) 261-277
14. Currier G.W., Chou J.C.Y., Feifel D., Bossie C.A., Turkoz I., Mahmoud R.A., and Gharabawi G.M. Acute treatment of psychotic agitation: a randomized comparison of oral treatment with risperidone and lorazepam versus intramuscular treatment with haloperidol and lorazepam. J. Clin. Psychiatry 65 (2004) 386-394
15. Daniel D.G., Zimbroff D.L., Swift R.H., and Harrigan E.P. The tolerability of intramuscular ziprasidone and haloperidol treatment and the transition to oral therapy. Int. Clin. Psychopharmacol. 19 (2004) 9-15
16. Eli Lilly and Company. Olanzapine (Zyprexa) US Prescribing Information (2006), Eli Lilly and Company, Indianapolis, IN, USA
17. Hedlund J.L., and Vieweg B.M. The Brief Psychiatric Rating Scale (BPRS). A comprehensive review. J. Oper. Psych. 11 (1980) 48-65
18. Janssen Pharmaceutica. Risperidone (Risperdal) Package Insert (2003), Janssen Pharmaceutica, Titusville, NJ, USA
19. Kay S.R., Fiszbein A., and Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 13 (1987) 261-276
20. Levy R.H. Sedation in acute and chronic agitation. Pharmacotherapy 16 (1996) 152S-159S (discussion 166S-168S)
21. Lieberman J.A., Perkins P., Belger A., Chakos M., Jarskog F., Boteva K., and Gilmore J. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol. Psychiatry 50 (2001) 884-897
22. McCreadie R.G. Managing the first episode of schizophrenia: the role of new therapies. Eur. Neuropsychopharmacol. 6 Suppl. 2 (1996) S3-S5
23. McEvoy J.P., Scheifler P.L., and Frances A. Expert consensus guideline series treatment of schizophrenia. J. Clin. Psychiatry 60 Suppl. 11 (1999) 1-80
24. Meehan K., Zhang F., David S., Tohen M., Janicak P., Small J., Koch K., Rizk R., Walker D., Tran P., and Breier A. A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. J. Clin. Psychopharmacol. 21 (2001) 389-397
25. Miller D.D. Atypical antipsychotics: sleep, sedation, and efficacy. Prim. Care Companion J. Clin. Psychiat. 6 Suppl. 2 (2004) 3-7
26. National Institute for Clinical Excellence (NICE). Clinical Guideline 1: Schizophrenia (2002) London
27. Ohlsen R.I., and Pilowsky L.S. The place of partial agonism in psychiatry: recent developments. J. Psychopharmacol. 19 (2005) 408-413
28. Overall J.E., and Gorham D.R. The brief psychiatric rating scale. Psychol. Rep. 10 (1962) 799-812
29. Pfizer. Ziprasidone (Geodon) Package Insert (2003), Pfizer, New York, NY, USA
30. Segal S.P., Akutsu P.D., and Watson M.A. Involuntary return to a psychiatric emergency service within twelve months. Soc. Work Health Care 35 (2002) 591-603
31. Wright P., Birkett M., David S.R., Meehan K., Ferchland I., Alaka K.J., Saunders J.C., Krueger J., Bradley P., San L., Bernardo M., Reinstein M., and Breier A. Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am. J. Psychiatry 158 (2001) 1149-1151
32. Wright P., Psych M.R.C., Lindborg S.R., Birkett M., Meehan K., Jones B., Alaka K., Ferchland-Howe I., Pickard A., Taylor C.C., Roth J., Battaglia J., Bitter I., Chouinard G., Morris P.L.P., and Breier A. Intramuscular olanzapine and intramuscular haloperidol in acute schizophrenia: antipsychotic efficacy and extrapyramidal safety during the first 24 hours of treatment. Can. J. Psychiatry 48 (2003) 716-721
33. Yildiz A., Sachs G.S., and Turgay A. Pharmacological management of agitation in emergency settings. Emerg. Med. J. 20 (2003) 339-346